New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
纽约和加利福尼亚州通过储存替代堕胎药物，为德克萨斯州可能的米非司酮禁令做准备
- New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this week.
- The alternative option, misoprostol, is FDA-approved to treat gastric ulcers, noted CNBC. But the use of misoprostol alone to induce abortions is endorsed by the World Health Organization and is used in countries where mifepristone is unavailable.
- Also Read: Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead.
- It will remain on the market if U.S. District Judge Matthew Kacsmaryk's order suspending mifepristone takes effect this week Saturday.
- More than half of abortions in the U.S. use a combination of mifepristone and misoprostol.
- Some U.S. abortion providers are prepared to offer misoprostol as a stand-alone treatment, CNBC reported citing Jenny Ma, senior staff attorney at the Center for Reproductive Rights, a legal advocacy group representing abortion providers worldwide. Ma also said that other providers might not be ready to switch to a misoprostol-only regimen.
- New York Gov. Kathy Hochul ordered the state health department to purchase 150,000 doses of misoprostol, a five-year pill supply. Hochul's announcement comes a day after Gov. Gavin Newsom said California has secured 2 million misoprostol pills.
- Hochul said she is working with New York's legislature to require private insurers to cover misoprostol when prescribed off-label for abortions.
- The Justice Department and Danco Laboratories, the distributor of mifepristone, have asked the U.S. 5th Circuit Court of Appeals to block Kacsmaryk's ruling by noon Thursday.
- Photo via Wikimedia Commons
- 纽约州和加利福尼亚州正在储备替代堕胎药物，以防得克萨斯州法官暂停美国食品药品管理局对主要药物米非司酮的批准的命令在本周晚些时候生效。
- CNBC指出，替代方案米索前列醇已获美国食品药品管理局批准用于治疗胃溃疡。但是，仅使用米索前列醇诱导堕胎得到了世界卫生组织的认可，并且在无法获得米非司酮的国家中使用。
- 另请阅读： 20多个州的总检察长对暂停堕胎药物批准敲响警钟：未来有 “毁灭性风险”。
- 如果美国地方法院法官马修·卡斯马雷克暂停米非司酮的命令在本周六生效，它将继续在市场上销售。
- 在美国，超过一半的堕胎同时使用米非司酮和米索前列醇。
- CNBC援引代表全球堕胎提供者的法律倡导组织生殖权利中心高级律师珍妮·马的话报道，一些美国堕胎提供者准备将米索前列醇作为独立治疗方法提供。马云还表示，其他提供者可能还没有准备好改用仅限米索前列醇的治疗方案。
- 纽约州州长凯西·霍赫尔命令州卫生部门购买15万剂米索前列醇，这是为期五年的药丸供应。Hochul宣布这一消息的前一天，州长加文·纽瑟姆表示加利福尼亚州已获得200万粒米索前列醇药丸。
- 霍赫尔说，她正在与纽约州立法机关合作，要求私人保险公司为标签外的堕胎处方提供米索前列醇的保险。
- 司法部和米非司酮的分销商丹科实验室已要求美国第五巡回上诉法院在周四中午之前阻止Kacsmaryk的裁决。
- 照片来自维基共享资源